China is racing to develop brain-computer interfaces (BCIs) that can be implanted rapidly through blood vessels, reducing surgical risks and enhancing patient access. Backed by major tech investors, Chinese firms are conducting trials and targeting significant market growth by 2030.
- Vein-inserted BCIs can be implanted in about 10 minutes
- StairMed Technology raised $163 million to support research
- China aims to create multiple global BCI leaders by 2030
What happened
Chinese companies and research institutes are accelerating efforts to commercialize brain-computer interfaces that can be implanted via vascular pathways rather than through invasive brain surgery. Firms like StairMed Technology are developing devices that navigate through the neck’s blood vessels to reach targeted brain regions, significantly simplifying and shortening the implantation procedure.
The Shanghai-based StairMed has garnered over 1.1 billion yuan (approximately $163 million) in funding from prominent investors such as Tencent Holdings and Alibaba. They have completed animal testing and are preparing for human trials. Xuanwu Hospital in Beijing is also conducting initial clinical studies using similar minimally invasive vascular approaches.
Why it matters
This vein-insertion method reduces the risk of serious complications associated with conventional brain surgeries that expose the cortex. Faster implantation — reportedly possible in as little as 10 minutes by experienced surgeons — can greatly expand patient accessibility to these life-enhancing devices, particularly for those with paralysis or severe motor impairments.
The BCI market is expected to grow rapidly, with the U.S. alone projected to reach $80 billion by 2035. China’s government has committed to nurturing at least two or three globally competitive BCI companies by 2030, demonstrating the sector’s strategic significance and the potential for Chinese firms to become international leaders.
What to watch next
Additionally, competition from startups in other countries developing vein-insertable BCIs, like the U.S.-Australia based Synchron, will influence innovation and market dynamics. How Chinese companies capitalize on domestic investment and policy support to scale clinical use and commercialization will shape their global standing in this emerging frontier.